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Despite active research in virotherapy, this apparently safe modality has not achieved widespread success. The immune response to
viral infection appears to be an essential factor that determines the eﬃcacy of oncolytic viral therapy. The challenge is determining
whether the viral-elicited immune response is a hindrance or a tool for viral treatment. NK cells are a key component of innate
immunity that mediates antiviral immunity while also coordinating tumor clearance. Various reports have suggested that the NK
response to oncolytic viral therapy is a critical factor in premature viral clearance while also mediating downstream antitumor
immunity. As a result, particular attention should be given to the NK cell response to various oncolytic viral vectors and how their
antiviral properties can be suppressed while maintaining tumor clearance. In this review we discuss the current literature on the
NK response to oncolytic viral infection and how future studies clarify this intricate response.
1.Introduction
The ﬁeld of oncolytic viral therapy is currently at a cross-
roads. With over twenty years of attention directed towards
oncolytic viruses (OV), clinical trials have been encouraging,
but have left investigators with the task of identifying
barriers that can be circumvented to achieve more successful
virotherapy. Some of the most prevalent obstacles include
the antiviral host response to OV, the angiogenic response
to viral infection, extracellular barriers to viral spread, and
ineﬃcient/nonspeciﬁc receptor-ligand interactions on target
cells [1]. Interestingly, various groups have also demon-
strated that an inability to achieve adequate antitumor
immunityalsorepresentsasigniﬁcantbarriertotumorclear-
ance[2].Inordertooptimizevirotherapyforclinicalsuccess,
the relevance of these barriers, along with the conﬂicting
roles of antiviral and antitumor immunity, must be clariﬁed.
While various groups have studied the host response to OV,
the natural killer (NK) cell response to various oncolytic
viruses has been less thoroughly investigated.
In order to appreciate both the current literature sur-
rounding the NK response to OV therapy and understand
how these cells can be targeted in future studies, it is essential
to understand the role of these cells in viral clearance
and tumor immunology. Interestingly, profound human
NK cell deﬁciencies have led to overwhelming herpes viral
infections, supporting the notion that this innate immune
eﬀector cell has speciﬁc recognition of, and control over,
viral infection [3–5]. Additionally, multiple reports have
associated NK cell levels with tumor regression [6–9]. Taken
together, these ﬁndings highlight potentially conﬂicting roles
for NK cells in oncolytic virotherapy. On the one hand,
the antiviral properties of these cells may be detrimental
to viral propagation and viral mediated tumor clearance.
Conversely,anactivatedNKresponsefollowingOVinfection
of tumors may stimulate NK-mediated antitumor immunity2 Advances in Virology
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Figure 1: The immune reaction to oncolytic viral infection is two-phased response. Within hours after infection, the innate immune
response consisting of NK cells, macrophages, and neutrophils is recruited to the site of infection and mediates initial viral clearance.
Following this response to infection, innate immune mediators, particularly NK cells, mediate the downstream adaptive immune response
that is a critical antitumor mediator. In order to reconcile this biphasic response, initial immune suppression targeting NK cells may be
required initially after viral infection followed by a period of immune stimulation to elicit antitumor immunity.
(Figure 1). While most studies to date have focused on the
dichotomous nature of the NK response, it is likely that a
morenuancedapproachwillbeneededinwhichtheantiviral
response to infection is initially suppressed while antitumor
immunity is selectively stimulated.
Investigators frequently attempt to correlate the success
of their oncolytic viral therapy with immune cell inﬁltration
following infection. Using this metric, NK cells have been
highlighted as a relevant factor in response to OV infec-
tion. However, signiﬁcantly less attention has been directed
towards the nature and relevance of this viral-induced NK
response. For example, what role do NK cells have in recruit-
ing activated macrophages following OV therapy? Does
OV administration induce a diﬀerent NK activation pro-
ﬁle compared to infection with its wild-type counterpart?
Does OV infection of tumor lead to the preferential NK-
mediated clearance of these virally infected cells compared
to uninfected tumor and therefore impeded viral oncolysis?
Are there discrepancies between activated NK cells that are
recruited in mice bearing xenograft tumors versus syngeneic
tumors? Lastly, is it possible to temporarily pharmacologi-
callymodulatetheNKimmuneresponsetoOV-infectedcells
in order to enhance OV therapeutic eﬃcacy? These are just
a few of the questions that should be considered as inves-
tigators move beyond just determining that these cells are
recruited following infection. In this review, we will discuss
the nature of the host response to OV infection, highlight
theclinicalrelevanceofNKcellsinantiviraldefense,consider
the literature surrounding the NK response to OV therapy,
and suggest areas for future investigation.
2.PlacingNK CellBiology intheOV Context
Although a corpus of evidence has delineated both the role
of NK cells in tumor clearance for various tumor models and
their role in viral eradication, the importance of NK cells in
responsetoOVtherapyisjustbeginningtobeappreciated.In
order to decipher their role in the OV context, it is important
to ﬁrst understand the basic properties of NK cell biology.
Human NK cells are divided into separate CD56bright and
CD56dim populations that diﬀer in their functional capacity
and localization [10]. Approximately 90% of circulating and
splenic NK cells are CD56dimCD16+, express perforin, and
possess cytotoxic capacity when interacting with target cells
[11]. In contrast, CD56brightCD16-NK cells are detected in
lymph nodes and tonsils, lack perforin, and readily produce
cytokines such as IFN-γ in response to stimulation with
IL-12, -15, and -18 [12, 13]. In mice, NK cells have been
diﬀerentiated into three subsets according to CD11b and
CD27 expression [14]. NK cell diﬀerentiation in mice occurs
from a relatively immature C11bdullCD27+ state to the
double positive CD11b+CD27+ and ultimately to the senes-
cent CD11b+CD27dull. Notably, both the double positive
and senescent NK cells have been demonstrated to secrete
IFN-γ and carry out cell-mediated cytotoxicity. While inves-
tigators have identiﬁed diﬀerential anatomical distributionAdvances in Virology 3
foreachtypeofNKcellinwildtypemice,therehavebeenno
examinations into the maturation state of NK cells within
the tumor microenvironment either in the absence or
presenceofOV.Despitethediﬀerencesindevelopmentaland
activation markers on NK cells in mice and humans [15], a
basic understanding of the role of NK cells in response to OV
therapy in mice establishes a framework for future studies in
clinical trials.
While certain NK cells are suﬃciently mature to produce
both cytotoxic and cytokine responses, these two func-
tions are products of the cytokine microenvironment. For
instance, type I interferon, IL-12, and IL-18 are critical for
the induction of NK activation [16]. Moreover, much like T
cellsrequire“priming”forfullactivation,IL-15hasbeenelu-
cidated as a cytokine that is critical for the priming function
of murine NK cells [15, 17]. While initial eﬀorts have exam-
ined the role of certain activating cytokines within the tumor
microenvironmentfollowingOVtherapy[18,19],additional
work is needed to understand their roles in OV clearance
and tumor killing.
NK cells are able to carry out their diverse repertoire
of activities through a detection system that relies on the
engagement of a variety of cell surface activating and in-
hibitory receptors on NK cells (Figure 2). Through the
bindingofthesereceptors,adynamicequilibriumisachieved
that diﬀerentiates the recognition of “self” cells from trans-
formed target cells. The activating NK cell receptors detect
thepresenceofligandsoncellsthatareina“distressed”state.
These include stress ligands in mice (e.g., RAE1, H60, and
MULT1)andhumans(e.g.,ULBP1-3andMICA/B)thatbind
to the NKG2D activating receptor on NK cells. Natural cyto-
toxicity receptors (NCRs) are a family of activating receptors
critical for mediating NK killing. They consist of NKp46
which is endogenously expressed on NK cells and NKT-like
cells in both mice and humans [20]; NKp44 which is solely
expressed on human NK cells, with constitutive expression
only after cytokine stimulation, and plasmacytoid dendritic
cells [21]; NKp30 which is exclusively expressed on resting
and activated human NK cells [22]. While the identity of lig-
ands for NCRs is a ﬁeld of intense investigation [23], recent
discoveries have identiﬁed inﬂuenza hemagglutinin (HA)
as an activating ligand for NKp46 and NKp44 [24]. Besides
mediating the eradication of tumor and virally infected cells,
NKp30 interacts with immature dendritic cells (imDCs).
Following NKp30 binding to an unknown ligand on imDCs
[25], the imDCs are subsequently either killed or develop
into mature DCs that can mediate a Th1 response [26]
culminating in tumor/viral eradication. To counteract this
process, human cytomegalovirus tegument protein pp65
impedes NKp30 activation through NKp30-CD3ζ receptor
dissociation and the concomitant circumvention of NKp30-
mediated maturation of dendritic cells [27, 28]. Known
activating ligands for NKp30 include two activating cellular
proteins. These include B7-H6 [29] ,ac e l ls u r f a c ep r o t e i n
associated with tumor formation and Bat3 [30] ,ar e l e a s e d
cellular stress protein. In addition to their activating recep-
tors, NK cells also possess an array of inhibitory receptors
that are used to survey cells for the absence of constitu-
tively expressed self-ligands. For instance, MHC-I expres-
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Figure 2: NK cell activation is mediated by a variety of cell surface
inhibitory and activating receptors that recognize cell surface
ligands on target cells. Viral infection, oncogenic transformation,
and cellular stressors result in the downregulation in ligands for NK
inhibitory receptors while concomitantly increasing the expression
ofNKactivatingligands.Despitethepresenceofbothactivatingand
inhibitory signals on target cells, the overall balance of these signals
dictates NK activation and target cell clearance.
sion is recognized by the inhibitory receptor killer cell
immunoglobulin-like receptors in humans, lectin-like Ly49
dimers in mice, and CD94-NKG2A heterodimer in both
species [15].
Taken together, by identifying cells that have absent
MHC-I expression and/or upregulation of stress or virally
encoded ligands for NK activating receptors, a target cell can
be susceptible to NK-mediated lysis. By characterizing the
NK ligand signature following OV infection and deciphering
the receptor-ligand interactions that are responsible for NK
recognition of virally infected cells, a mechanistic under-
standing can potentially guide the development of ther-
apeutic approaches to selectively target the NK receptors
implicated in either the anti-OV or antitumor response.
3. The Host Response to OV Therapy
The rapid response of innate immunity, consisting of NK
cells, monocytes, macrophages, and neutrophils provides an
initial and potent line of defense for the host and limits
initial viral infection, replication, and spread; facilitates4 Advances in Virology
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Figure 3: Innate immune eﬀector cells, including NK cells and macrophages, represent an initial barrier to viral infection, replication, and
spread.Followinginfection,NKcellsarerecruitedtothesiteofinfectionandadoptanactivatedphenotype.ThroughtheirIFN-γ production,
theyalsofacilitatethematurationandactivation ofmacrophages whichadopt aninﬂammatory“M1”phenotype. Lastly,macrophages create
a feedback loop by producing a variety of inﬂammatory cytokines that mediate NK activation. This inﬂammatory response creates a potent
antiviral microenvironment while also communicating with the adaptive immunity.
the maturation of antigen presenting cells; communicates
with the adaptive arm of the immune system to regulate its
response. Due to the rapid decline in viral titers within days
of inoculating various oncolytic viruses [31, 32], the innate
immune response has been implicated as a critical factor
in this response. While neutrophils are the ﬁrst antiviral
responders that are recruited to a site of infection, eﬃcient
viral clearance at the cellular level requires both NK cells and
monocyte-derived cells. Activated NK cells mediate direct
lysis of infected target cells by releasing cytotoxic granules
containing lytic enzymes [33] or by binding to apoptosis-
inducing receptors on target cells [34]. NK cell-mediated
preferential lysis of HSV- or vaccinia-virus-infected cells has
been shown to prevent viral dissemination to neighboring
cells [35]. While recruitment of NK cells to infected tumor
tissue has correlated with reduced viral spread and OV
eﬃcacy, IFN-γ production by NK cells has also been shown
tosetthestageforthesubsequentadaptiveimmuneresponse
[36, 37].
Apart from NK cells, macrophages also play a critical
role in OV clearance. Upon viral infection, resident or
recruited macrophages initially secrete IL-12 to activate NK
cells while NK cells complete the feedback loop by secreting
IFN-γ—theprototypic macrophageactivator,withoutwhich
macrophages cannot clear microbes [36]( Figure 3). In fact,
recruitment of inﬁltrating monocytic cells has been shown
to coincide with clearance of over 80% of HSV-derived
oncolytic viral particles [38, 39]. Increased intra-tumoral
presence of macrophage/microglia cells has also been
reported in human patients treated with adenovirus [40, 41]
or HSV-1-derived OV [42] indicating the global signiﬁcance
of macrophages in OV therapy.
Despite their antiviral properties, NK cells have pleio-
tropic eﬀects that may also be critical in tumor killing. NK
cells have been shown to augment the tumoricidal eﬀects in
various models. This includes the most well-studied example
of a melanoma model in which NK cells have been deﬁned
as an essential cellular component for VSV eﬃcacy [43].
In this model, NK cells functioned synergistically with the
adaptive antitumor immune response, launched in response
to viral antigens expressed by tumor cells. Therefore, it
appears that NK cells can serve a dual function—both as
potential inhibitors of viral replication and as critical medi-
a t o r st oe s t a b l i s ha ne ﬀective antitumor immunity following
viral antigen presentation within the tumor cells. These
ﬁndings emphasize the impact of variations in tumor
models, anatomical location of the tumors, and properties
of the viruses that are being tested [2].
In future studies, a reﬁned approach will be needed
to manipulate individual cell populations while considering
both the timing and nature of the intervention in order
to maximize therapeutic regimens. One promising, albeit
simplistic, approach will be to combine OV inoculation with
transient immunomodulation in order to achieve initial viralAdvances in Virology 5
replication, followed by restoration of immune activity to
harness the immunotherapeutic potential of virotherapy.
4. NK Deﬁciencies
NK cell deﬁciencies, while being a rare phenomenon, pro-
vide valuable information about the role of these cells in
antimicrobial defense and potentially the NK response to
OV. While these deﬁciencies are relatively uncommon, they
indicate the essential nature of these cells in host defense.
The most informative group of disorders involves an isolated
human NK cell deﬁciency that is associated with a speciﬁc
gene mutation [4]. The only known human gene alteration
resulting in an isolated NK cell deﬁciency results from
a polymorphism in CD16, the IgG Fc receptor which is
activated following binding to IgG. In this polymorphism,
the CD16 epitope recognized by mAb B73.1 is changed by
aT→ A substitution at position 230 resulting in L48 →
H[ 4]. Individuals homozygous for this alteration have phe-
notypically normal NK cells but are not recognized by mAb
B73.1 [44, 45]. Several individuals have been documented
to have a homozygous 48H phenotype and they reported
to have recurrent viral infections. In particular, a 5-year-old
girl was documented to have frequent respiratory infections,
recurrent HSV stomatitis, and recurrent herpetic whitlow
[45]. This child was deﬁcient in NK cell cytotoxicity against
K562 target cells but had normal antibody-dependent cellu-
larcytotoxicity(ADCC).Takentogether,this48Hphenotype
suggests the importance of this epitope in resistance to viral
infections.
A second group of NK cell deﬁciencies result from
unknown gene mutations. The most striking example of
humanNKcelldeﬁciencyisfromafemaleadolescentwithan
absolute NK cell deﬁciency based on a lack of lymphocytes
expressing CD56 or CD16 and an absence of both NK cell
cytotoxicity and ADCC. This patient presented with dissem-
inated, life-threatening varicella infection and subsequently
developed both CMV pneumonitis and cutaneous HSV [5].
There have also been reports of individuals with functional
NK deﬁciency in which NK cells are present as a normal per-
centage of peripheral blood lymphocytes, but are deﬁcient
in activity. For example, four patients have been reported
with widespread or invasive HSV disease, all with basal NK
cell cytotoxicity against HSV-infected ﬁbroblasts [46].
Although isolated NK cell deﬁciencies present the oppor-
tunity to understand NK cell speciﬁc genes and NK cell roles
in human antimicrobial defense, a variety of other diseases
have NK cell deﬁciency as a component. For instance, in
Griscelli syndrome patients have variable immune deﬁcien-
cies that typically include a marked reduction in NK cell
cytotoxicity but an ability to induce cytotoxicity upon IFN-α
orIL-2stimulation[47–49].Despitethisvariableresponsive-
ness, patients with this syndrome have a propensity for EBV
and HSV infections [47]. In leukocyte adhesion deﬁciency
(LAD), patients have elevated peripheral leukocytes and in
some patients, a corresponding recurrence of HSV infection
[50, 51]. In these patients, the ability of NK cells to me-
diate cytotoxicity, ADCC, or kill HSV-infected target cells is
severely attenuated. In LAD, there are a variety of mutations
in the β2 integrin CD18 [52]. This results in the inappropri-
ate expression of various key adhesion complexes including
LFA-1 (CD11a/DC18) and Mac-1 (CD11b/CD18). Notably,
LFA-1 associates with the immunoglobulin-like activating
receptor DNAM-1 [53]. Taken collectively, the ﬁndings from
bothisolatedhumanNKcelldefectsanddiseasesthatinclude
NK cell deﬁciencies suggest that human NK cell activity
is especially important in limiting viral infection and may
similarly attenuate oncolytic viral propagation.
5.The InterfacebetweenNKCellsand
Oncolytic Viral Therapy
5.1. NK Cells and Antitumor Immunity. In fully immuno-
competent animal models, the variables that ultimately
determine clinical success are the amount of viral replication
inside the tumor, the antiviral immune response elicited by
viral infection, and the stimulation of an antitumor immune
response. However, diﬀerences in oncolytic viral vectors,
tumor models, and the anatomical locations of tumors
add a layer of complexity that makes broad conclusions
about host immunity diﬃcult to achieve. Innate immune re-
sponses have the potential of mediating cytotoxicity directly
against tumors while simultaneously mediating downstream
immune response [54]. Among the innate immune cell
compartment that mediates this response, NK cells stand out
as a key cellular factor [55]. While the presence of NK cells
within human tumors is associated with a positive prognosis
[6–9], their inﬁltration within many tumors is often sparse
[56, 57]. Since NK cells possess both antiviral and antitumor
properties, it is not surprising that their involvement is
equally controversial. While there are examples of studies
that have found no involvement of NK cells in response to
oncolytic viral infections [58, 59], the majority of studies
ﬁnd that they are relevant in some capacity. To start, we will
focus on studies that both highlight the need of achieving
antitumor immunity and determine the essential role of NK
cells in mediating this response.
One of the ﬁrst reports to mechanistically describe the
essentialnatureofantitumorimmunitywastheworkofDiaz
et al. in which VSV was administered intratumorally for the
treatment of an immunocompetent B16 melanoma model
[43]. In this study, depletion experiments were performed to
demonstrate that tumor regression was achieved in a CD8
and NK cell-dependent manner. While markers of NK cells
and CD8 T-cell activation were not extensively examined,
the authors did observe that CD8 priming correlated with
increased cell counts in both the tumor and draining lymph
nodes; however, NK cell numbers remained unchanged
following infection. Corroborating the relevance of these
ﬁndings, the treatment of prostate cancer with reovirus over-
rode the prominent immunosuppressant milieu of prostate
adenocarcinoma [60, 61] and elicited an antitumor CD8
T-cell response along with prominent NK cell inﬁltration
[62]. Miller and Fraser also found that intratumoral therapy
with oHSV for metastatic melanoma was abrogated in
syngeneic models lacking NK and T-cell subsets [63]. Lastly,6 Advances in Virology
inoculation of HSV-1716 induced the production of IFN-
γ inducible chemokines from human DCs along with the
migration of NK and CD8 cells into murine tumors [64].
Taken collectively, these ﬁndings from various tumor models
treated with VSV, reovirus, and oHSV highlight the apparent
relevance of NK and T cells as mediators of antitumor ef-
ﬁcacy [2].
Interestingly,arecentPhaseItrialexaminingintravenous
administration of oncolytic reovirus found that CD8 and
NK cells increased by 33% and 38%, respectively, following
OV infection [65]. These ﬁndings appear to highlight the
relevance of these cellular components in the clinical setting.
Despite these observations, increases in immune cell num-
bersdonotnecessarilycorrelatewithimmunecellsactivation
inresponsetoinfection.Asaresult,futurestudiesareneeded
to evaluate the phenotypic proﬁle and relevance of each
immune cell component following oncolytic viral infection.
In addition to the CD8 and NK response, Diaz et al.
examined the signiﬁcance of regulatory T cells (Tregs) in
their model [43]. Following viral inoculation, increased
numbers of Tregs were detected within the tumor. Surpris-
ingly, Treg depletion did not increase antitumor eﬃcacy by
relieving the suppression of antitumor CD8 cells; rather,
the antiviral immune response was signiﬁcantly enhanced
following Treg depletion, resulting in both decreased viral
titersanddecreasedOVeﬃcacy.Inthismodel,theseﬁndings
suggest that Treg suppression is active at the level of antiviral,
rather than antitumor immunity.
The treatment of B16 subcutaneous tumors and lung
metastasis can also be treated with intravenous VSV, albeit
using a diﬀerent mechanism. In the study by Kottke et al.,
vascular leak syndrome (VLS) correlated with enhanced
oncolytic VSV localization to subcutaneous and metastatic
lung tumors [66]. VLS is induced following IL-2-mediated
endothelial cell injury which was exacerbated with Treg
depletion [67, 68]. The authors hypothesized that this
endothelial damage and concomitant vascular permeability
created an environment that facilitated viral access from the
circulation to the tumor. Interestingly, NK cells were critical
forVLS-mediatedlocalizationandspreadthroughthetumor
while also allowing for the continued delivery of virus to
tumors in the presence of previously vaccinated mice [66].
In contrast to the work by Diaz et al. [43], the induction
of VLS through Treg depletion induced a markedly diﬀerent
immune response to OV infection [66]. While IL-2 expands
the pool of NK cells in vivo, these cells are kept in check
by Tregs which are similarly expanded by IL-2. Thus,
depletion of Tregs appears to result in hyperactivated NK
cells manifesting in enhanced VLS, cytokine production, and
cytotoxic eﬀector functions [66]. Moreover, this eﬃcacious
response was recapitulated in the same tumor model using
i.v. administration of reovirus combined with IL-2 and
cyclophosphamide (CPA) [69]. When given at low doses,
CPA has been demonstrated to enhance immune responses
against tumors through transient depletion of Tregs [70,
71]. Consistent with the ﬁndings with VSV combined with
IL-2 and Treg depletion [66], reovirus/IL-2/CPA cotherapy
achieved an activated NK phenotype that achieved signiﬁ-
cant tumor regression [69].
Somewhat surprisingly, however, this state of NK cell
hyperactivation, which presumably includes antiviral prop-
erties,correlateswithincreasedVSVlocalization,replication,
and spread. These ﬁndings suggest that in a VLS virotherapy
model, the antiviral properties of hyperactivated NK cells are
overridden by their ability to localize systemically injected
virus to the tumor. These ﬁndings were also in contrast
to the ﬁndings of Diaz et al. [43] in which Treg depletion
was detrimental for CD8/NK cell-mediated eﬃcacy of IT
administration of VSV. Thus, Treg depletion clearly has
positive and negative outcomes and emphasizes the need
to consider opposing interactions between antitumor and
antiviral immune cells.
While the ﬁeld of oncolytic viral therapy is built upon
the premise that a small initial inoculum will go through
progressive rounds of viral replication in order to achieve
tumor clearance, the work of Galivo et al. used a mutant
form of VSV to modify this fundamental principle [72].
Rather than just relying on viral oncolysis, it is becoming
increasingly apparent that antitumor immunity is a critical
factorforVSV-mediated eﬃcacy.This wasclariﬁedby Galivo
et al. in which a single replication cycle VSV vector, but not
a replication defective or UV inactivated virus, was found
to achieve equal therapeutic eﬃcacy compared to a fully
replication competent VSV vector [72]. Thus, the ability of
oncolytic VSV to proceed through multiple rounds of viral
replication is unnecessary; rather, the immune response to
intratumoral injection of a live, viable virus that is able to
express its genome is the essential eﬀector mechanism for
tumor clearance [72]. Further supporting this premise, both
viruseselicitedanearlyidenticalNKandCD8T-cellimmune
response, thereby conﬁrming that antiviral immunity and
the ability to elicit an acute proinﬂammatory response is an
essential component for achieving antitumor eﬃcacy that is
seen in the B16 model [72].
AnadditionalmechanisticcomponentforVSV-mediated
clearance of B16 is the role of IL-28 and NK cells in this
process. In the study by Wongthida et al., IL-28 expression
following VSV infection is identiﬁed as a key mediator
of antitumor immunity [73]. Both the expression of IL-28
and the presence of its cognate receptor on B16 tumors were
required for therapeutic eﬃcacy. Moreover, IL-28-mediated
activation of bone marrow cells to induce bystander cyto-
toxicity against B16 while maintaining an environment
c o n d u c i v ef o rv i r a lr e p l i c a t i o na n ds p r e a d[ 73]. Although
IL-28 was produced from GR1+ and Macs3+ and not NK
cells, depletion of NK1.1 cells eliminated cytotoxicity against
B16 cells. It appears that this is coordinated through IL-28
induction of NK ligands on B16 cells and IL-28-mediated
activation of IFN-γ production from NK cells (Table 1).
Thus,IL-28wasidentiﬁedasanovelmediatorofNKcellacti-
vation that is essential for VSV therapeutic eﬃcacy. Further
work is needed to extrapolate these ﬁndings to other tumor
models and oncolytic viral vectors; however, this initial
report suggests that screening tumors for IL-28 receptor
may represent a useful prognostic marker for predicting
therapeutic response [73].
A recent study by Granot et al. has added additional
evidence to the relevancy of NK cells in mediating viralAdvances in Virology 7
Table 1: Relevant NK receptor-ligand interactions in the ﬁeld of
virotherapy.
Treatment Altered NK ligand or receptor Reference
IL-28
↑ RAE-1 [73]
↑ H60 [73]
↑ MULT-1 [73]
Valproic acid
↓ NKp30 and NKp46 [75]
↑ MICA/B [76]
VSV+UL141 ↓ CD155 [77]
HSV
↓ MICA [78]
↑ NCR ligands [79]
Parvovirus ↑ CD155 [80]
ΔNS1 inﬂuenza type A ↑ Inﬂuenza hemagglutinin [81]
mediated tumor clearance. Using a replication deﬁcient
Sindbis virus to treat SCID mice bearing ES-2 ovarian car-
cinoma xenografts, the authors found that tumor clearance
was dependent upon the presence of functional NK cells
[74]. In addition, the eﬃcacy of a recombinant Sindbis/IL-
2 expressing virus was dependent upon NK cells and
IFN-γ production that ultimately mediated macrophage
polarization towards an inﬂammatory M1 phenotype. These
ﬁndings highlight the role of NK-mediated tumor clearance
in immunodeﬁcient mice treated with a replication defective
viruses. It is important to interpret these ﬁndings in the con-
text that viral replication was not a goal with this viral vector.
Moreover, it is important to note that NK cells were the key
antitumor mediator in the SCID mice used in the experi-
ment. As a result, future work will need to discriminate (a)
whether NK cell activity is still essential when viral replica-
tion is desired, and (b) the relative importance of NK cell
coordinated adaptive antitumor immunity in immunocom-
petent models.
5.2. Pharmacologic Modulation of the Host Response to OV.
While antitumor immunity can be a critical tool for OV
eﬃcacy, various pharmacologic cotherapies have also been
used to counteract this response and synergize with OV
therapy. For instance, the complement system is rapidly
activated following viral infection and is intended to directly
neutralize virus; consequently, abrogating this response
could potentially enhance OV eﬃcacy. This question was
addressedbyusingcobravenomfactorwhichdepletestheC3
component of the complement system and was subsequently
shown to enhance OV infection [82].
Cyclophosphamide(CPA)hasalsobeenusedtoattenuate
antibody-mediated activation of the complement system,
serum neutralization of virus, and reduce peripheral blood
mononuclear counts that are responsible for producing an
antiviral cytokine response [19]. Due to the pleiotropic
immunosuppressive nature of CPA and its ability to halt the
antiviral immune response, in vivo CPA treatment signiﬁ-
cantly reduced viral clearance and increased viral propaga-
tion while reducing immune cell ﬁltration [19, 83]. Taken
together, these ﬁndings suggest that targeting the immune
response to OV therapy is a particularly useful modality
towards achieving enhanced OV eﬃcacy.
While angiogenesis provides resources to growing tu-
mors, this increased vascularity is also associated with
increased immune cell traﬃcking. As a result, antiangiogenic
agents have the potential of reducing not only tumor growth
but also the antiviral tumor microenvironment. For exam-
ple, cilengitide is an antiangiogenic, cyclic RGD (cRGD)
peptide that was originally identiﬁed as antagonists for the
integrins αvβ3a n dαvβ5[ 84]. cRGD also limits leukocyte
recruitment to sites of inﬂammation [85], reduces myeloid
cell adhesion and transendothelial cell migration [86, 87].
When combined with OV, cRGD limited both OV-mediated
inﬂammatory gene expression and CD45 leukocyte recruit-
ment [18]. This reduced inﬂammatory response resulted in
increased OV propagation in vivo and signiﬁcantly enhanced
therapeutic eﬃcacy of OV in animals with intracranial
tumors [18].
An additional pharmacologic approach that has been
demonstrated to enhance OV therapy is the use of the
histone deacetylase inhibitor valproic acid (VPA). VPA has
been shown to enhance the eﬃcacy of oncolytic HSV [88]
through the inhibition of IFN-I, STAT-1, PKR, and PML
signaling within infected glioblastoma cells. By targeting
intracellular mediators that are responsible for creating an
antiviral state [89], this therapeutic approach targets the
antiviral host response prior to the recruitment of antiviral
cellular mediators.
5.3. NK Cells and Antiviral Immunity. Despite a number of
studies suggesting that natural killer cells are a critical com-
ponent for achieving tumor clearance following oncolytic
viral therapy, the deleterious nature of innate immunity
has also been well documented with immunosuppressive
cotherapies that enhance OV eﬃcacy. Mathematical mod-
eling has previously shown that the timing of the antiviral
innateimmuneresponsetoOVcanbedetrimentaltotherapy
[90].Avarietyofimportantchangesassociatedwithantiviral
immunityoccurinthetumormicroenvironmentinresponse
to oHSV treatment of malignant GBM. These include pro-
foundincreasesinIFN-γ transcriptandproteinlevels;upreg-
ulation of IFN-γ inducible chemokines; increased hyper-
permeability with an associated inﬂammatory cell inﬁltrate;
a rapid rise in an inﬂammatory transcriptome including
type I interferon, TNFα,i N O S ,a n dI L - 1 5[ 18, 32, 83, 91].
Studies in multiple tumor models and oncolytic viruses
haveobservedarapiddeclineinviraltitersthatoccurswithin
days of inoculating various oncolytic viruses [32], suggesting
that impediments are in place that limits successive rounds
of viral replication. Using a GBM model, the clearance of
over 80% of oHSV occurs in an IFN-γ dependent manner
and corresponds with the rapid recruitment of NK cells
and peripheral macrophages into the site of viral infection,
suggesting that this response is a potential factor mediating
oHSV clearance [64]. Moreover, transient immunomod-
ulation with cyclophosphamide attenuated NK cell and
macrophagerecruitmenttothesiteofoncolyticHSV-1infec-
tion while resulting in profoundly increased viral titers and8 Advances in Virology
tumor clearance. Apart from HSV-1-derived OV, CPA has
also been shown to increase the oncolytic capacity of other
OVs derived from HSV-2 [92], adenovirus [39],and reovirus
[69, 93]. In fact, based on the promising preclinical results
seenwithCPAandOV,thecombinationofCPAwithmeasles
virus is currently being evaluated for safety and eﬃcacy in
human patients [94]. Similarly, clinical trials of reovirus with
CPA (clinicatrials.gov, NCT01240538) and adenovirus with
CPA (A. Hemminki, personal communication) are being
conducted.
The ﬁnding that CPA enhances OV therapy through
the suppression of immune cell recruitment was validated
through a study demonstrating that macrophage depletion
enhanced the eﬃcacy of oHSV therapy in glioblastoma
[91]. Clodronate encapsulated in liposomes is engulfed by
phagocytic cells resulting in intracellular accumulation of
apoptosis inducing clodronate [95]. When combined with
OVtherapy,CL-mediateddepletionofperipheralphagocytic
cells resulted in a 5-fold increase in OV titers in intracranial
glioblastoma. While these ﬁndings partly recapitulated the
eﬀect of CPA on OV replication, they were unable to achieve
enhanced in vivo survival demonstrated with CPA [91]. A
potential reason for these ﬁndings may relate to the inability
of clodronate to cross the blood brain barrier, thereby limit-
ing its ability to deplete phagocytic microglial cells in addi-
tion to peripheral macrophages. Alternatively, macrophages
may represent just one of multiple barriers present within
the innate immune response to OV. In fact, a study by
Breitbach et al. found that neutrophil depletion increased
oncolytic viral titers and enhanced tumor clearance [96].
These ﬁndings suggest that OV replication may be lim-
ited by cellular components of the innate immune system
shortly after viral infection. While we have previously
demonstrated that microglia and macrophages play a critical
role in limiting the therapeutic eﬃcacy of OV [91], the
role of NK cells has received less attention. In a series
of two separate studies, Altomonte et al. detected NK cell
inﬁltration into hepatocellular tumors treated with VSV and
demonstrated a critical role for NK cell-mediated viral clear-
ance in this model. First, intratumoral VSV replication and
tumor killing was signiﬁcantly enhanced in mice depleted
of NK cells [97]. Second, a recombinant VSV encoding
a viral chemokine binding protein (equine herpesvirus-1
glycoprotein G) attenuated NK cell recruitment, enhanced
viral titers and tumor necrosis, and dramatically increased
the overall survival of tumor-bearing mice compared to
mice treated by parental VSV [97]. Due to the broad range
of binding partners of the chemokine binding protein, an
additional recombinant VSV encoding UL141 was created
in order to more speciﬁcally inhibit NK cell recruitment
and activation [77]( Table 1). UL141 is derived from human
CMV that inhibits NK cell activation by blocking cell surface
expression of CD155 on infected cells, thereby attenuating
DNAM-1 mediating signaling on NK cells. In this study,
rVSV-UL141 similarly enhanced virotherapy by speciﬁcally
targetingtheNKresponsetoviralinfection[77].Theseseries
of ﬁndings suggest that NK cell recruitment and activation,
at least in some models, can be detrimental to viral oncolysis
and should be circumvented.
BasedonﬁndingsthatoHSVelicitsbriskNKrecruitment
to the site of infection and CPA modulation of innate
immunity enhances oHSV-mediated glioblastoma killing
[18, 19, 32, 83, 90, 98], the functional relevance of these
cells in vivo brain tumor models remains unclear and
additional studies willbeneeded to determine this. Themost
recent clinical trial for oncolytic HSV in recurrent glioblas-
toma patients attempted to determine evidence of HSV
replication and the extent of immune inﬁltration into the
tumormicroenvironmentfollowingOVadministration[42].
While viral replication was observed in a portion of the
patientsenrolledinthestudy,therewassigniﬁcantvariability
invirallevelsbetweenpatients.Theseﬁndingsareincontrast
to the assumption in the ﬁeld of OV therapy that even
small initial inoculums should amplify signiﬁcantly fol-
lowing successive rounds of viral replication [91, 99–101].
Additionally,immunohistochemical(IHC)analysisoftumor
tissue demonstrated that G207 administration elicited a
robust increase in CD3, CD8, CD20, and HAM56 staining.
Additionally, testing of the genetically engineered mutant
adenovirus (ONYX-015) in a phase I trial for glioblastoma
provided similar results. Notably, when biopsies were taken
fromrecurrenttumors,asigniﬁcantinﬂammatory,mononu-
clear inﬁltrate was observed within the tumor microenvi-
ronment. Notably, in both of these studies, staining with
the pan-NK maker CD56 was not included. These collective
IHC ﬁndings are consistent with our preclinical ﬁndings
[18, 32] and suggest that OV infection/replication causes
the recruitment of inﬂammatory inﬁltrates into the site of
viral infection. The nature of this histological feature is
uncertain. For example, it is unclear whether these ﬁndings
correlate with a potential beneﬁt by stimulating an antitu-
mor immune response or a detriment by eliminating OV
initially after infection thereby preventing initial rounds
of viral replication within the tumor. Taken together, the
ﬁndings from these clinical trials demonstrate the need for
a clearer understanding of the host-based factors and cellular
mediators that are responsible for limiting viral infection,
replication, and spread. By clarifying the host response to the
virus, subsequent clinical trials can be designed to modulate
these obstacles to viral propagation and achieve enhanced
OV eﬃcacy.
5.4. NK Cell Interactions with OV Infected Cells. Despite the
conﬂicting viewpoints that NK cells are either a beneﬁt or
a hindrance to OV eﬃcacy, most investigators would argue
that NK cells and their place within innate immunity have a
critical role in achieving success with this therapeutic modal-
ity [2]. As a result, the knowledge gained from uncovering
the mechanistic signals governing NK-mediated recognition
of OV infected cells has the potential of beneﬁting both
schools of thought. For instance, in cases where the NK
response is deleterious to OV eﬃcacy, it may be necessary to
design oncolytic viruses that express decoys or suppressors
of NK activating ligands or combine the oncolytic virus
with cotherapies that achieve similar NK avoidance of oHSV
infected target cells. In tumors where NK-mediated killing
is beneﬁcial to OV therapy, the opposite approach could
be used so that the oncolytic virus is combined with anAdvances in Virology 9
immunostimulatory agent that heightens the expression of
critical NK activating ligands. In either case, it will be
necessary to uncover the underlying signals that mediate NK
recognition of OV infected tumor cells.
NK cells are able to carry out their diverse repertoire
of activities through a detection system that relies on the
engagement of a variety of cell surface activating and
inhibitory receptors on NK cells that bind MHC class I
and class I-like molecules (Figure 2). Through the binding
of these receptors, a dynamic equilibrium is achieved that
diﬀerentiatestherecognitionof “self”cellsfrommalignantly
or virally transformed target cells. While a number of viral
vectors are being tested for the treatment of an equally
diverse array of tumors, studying the NK response to oHSV
infection of GBM, for example, can be extended to various
virotherapy models. GBMs are readily killed by NK cells
in vitro [102], and despite an intense immunosuppressive
tumor microenvironment as the GBM progresses, a recent
report found that peripheral NK numbers were not altered
in patients with GBM [103]. NK cells have also been
demonstratedtopreferentiallylysevirallyinfectedtargetcells
through either the elaboration of cytotoxic granules con-
taining lytic enzymes or through the binding of apoptosis-
inducing receptors on target cells [33]. Through the expres-
sion of both virally and tumor/stress associated ligands for
NKactivatingreceptors,atargetcellsuchasaninfectedGBM
can become susceptible to NK-mediated lysis. Countering
this is the production of TGF-β and related molecules by the
refractoryGBMcellsthatimpedebothNKcellproductionof
IFN-γ [104] and the ability of NK cells to directly lyse tumor
cell targets [105].
Recent discoveries have explored the role of HSV-1
infection in modulating NK activating ligand expression.
HSV-1 infection of ﬁbroblast cells, through its immediate
early gene product ICP0, resulted in increased susceptibility
to NK-mediated lysis in an MHC-I independent fashion
[79]. NK activation was achieved independently of the NK
activatingreceptorNKG2D[79].Rather,NKstimulationwas
elicited through the expression of an unknown ligand(s) of
the NCRs on the cell surface of infected cells. Moreover,
HSV infection was subsequently found to downmodulate
NKG2D ligand expression due to late viral gene products
[78]( Table 1). These ﬁndings demonstrate the modulation
of ligands for NK activating receptors following wild type
HSV infection; however, neither the identity of these ligands
nor the nature of their cooperative binding to NK activating
receptors is currently resolved.
Beyond cell-mediated viral clearance, NK cells are potent
producers of IFN-γ [104]. In the context of oHSV therapy,
the detrimental role of this antiviral cytokine has been
uncovered through an IFN-γ depletion study that resulted
in enhanced intratumoral viral titers [32]. Additionally, IFN-
γ is vitally important in the activation of macrophages,
thereby facilitating their ability to kill both viral and obligate
intracellular pathogens [106]. Collectively, these ﬁndings
demonstrate the critical nature of NK cells in coordinating
the antiviral response to oHSV therapy.
A number of groups have also studied the ability of
human glioblastomas to induce NK cell cytotoxicity. Based
ontheirexpressionproﬁleofligandsforactivatingNKrecep-
tors [102, 107], NK cells have been demonstrated to actively
lyse a variety of glioblastoma cells in a NKp46 and DNAM-1
dependent manner [102].
The mechanism of NK-mediated cytotoxicity in other
oncolytic viral models is also being explored. Recently, work
by Bhat et al. found that oncolytic parvovirus infection
of PDAC cell lines resulted in increased IFN-γ,T N F α,
and MIP1a/b release from NK cells in coculture [80].
Moreover, parvovirus infection appeared to sensitize virally
infected tumors cells to NK-mediated killing through the
downregulation of MHC-I, enhanced expression of NK acti-
vating ligands such as CD155, and involvement of multiple
NK activating receptors including NCRs, DNAM-1, and
NKG2D [80]. Based on the ﬁndings that target cells infected
with wild type inﬂuenza A virus (IAV) were exquisitely
sensitive to NK-mediated lysis through NKp46 recognition
of HA expressed on virally infected targets, an oncolytic
IAV was developed. This novel virus lacks the NS1 gene
and grows eﬃciently in IFN-resistant malignant cells with
concomitant Ras overexpression [108]. Using the ΔNS1 IAV
infected prostate cancer cells, Ogbomo et al. found that NK
cells overrode MHC-I inhibition and exhibited rapid ERK
activation, increased degranulation, and heightened NKp46-
mediated target cell lysis compared to uninfected cells [81].
These ﬁndings suggest that second-generation versions of
these viruses that coexpress an NK activating cytokine such
as IL-2 or IL-12 may be a useful tool in activating NK cells
in vivo, particularly in cases where the immunosuppressive
environment of the tumor results in resistance to NK-
mediated lysis.
By deciphering the critical receptor-ligand interactions
that are responsible for NK activation following viral in-
fection, this has the potential of paving the way for the
development of novel therapeutic approaches. This can be
achieved by either the selective blockade of NK receptors
implicated in the anti-OV response or the development of
ways to stimulate the critical receptor-ligand interactions
that are essential for downstream immunotherapy.
6.FuturePerspectives
Nearly two decades after the ﬁrst published report of
oncolytic viral therapy [40], investigators using these viruses
have made remarkable progress in their preclinical test-
ing and evaluation in clinical trials. Moreover, the recent
approval of the H101 oncolytic adenovirus in China [109],
the numerous clinical trials in place within the United
States and Europe, and the acquisition of BioVex by Amgen
suggest that virotherapy will gradually enter the arma-
mentarium of tomorrow’s physicians. In order to achieve
widespread clinical applicability, however, certain obstacles
must be overcome. For instance, infected cells have various
antiviral defense mechanisms that must be circumvented
to achieve sustained viral replication; however, circum-
venting this response must be countered with concerns
about uncontrolled viral replication and toxicity. Addition-
ally, host immunity, particularly innate immunity, is a ﬁrst10 Advances in Virology
line of defense against foreign pathogens that has been
demonstrated to impede virotherapy; however, immune
suppression potentially impedes the antitumor immune
response that has been shown to synergize with viral oncoly-
sis. Lastly, coadministration of pharmacological agents that
cooperate with viral mediated tumor clearance shows sig-
niﬁcant promise; however, the comparative eﬀectiveness of
treating various tumors with the appropriate virus/drug
combination must be thoroughly evaluated in clinical trials.
In recent years, signiﬁcant attention has been directed
towards the host immune response to oncolytic viruses.
In particular, the role of initial immune responder cells,
including NK cells, macrophages, and neutrophils, has been
questioned. With their antiviral and antitumor properties
combined with their ability to mediate macrophage activa-
tion, the NK cell response to virotherapy has elicited sig-
niﬁcant attention.
Despite recent progress, there are certain challenges that
shouldbe addressed in orderto expand our knowledge ofthe
NK response to OV therapy. To date, limitations in mouse
strain susceptibility to certain oncolytic viral vectors have
impeded the ability to evaluate the host immune response
in fully immunocompetent animal models [110, 111]. Thus,
there is an increasing need to study the NK response to
OV in syngeneic, orthotopic tumor models that include
the presence of tumor initiating cells and recapitulate the
immunosuppressive tumor microenvironment that is fre-
quently found in human cancers.
In order to fully investigate the role of NK cells following
OV infection, future studies should also attempt to test OV
inasyngeneicmousemodelwithspeciﬁcNKdeﬁciencies.By
testing for OV eﬃcacy and downstream immune cell activa-
tion, including macrophage and T-cell polarization, in each
of these groups, it would be possible to delineate the critical
NK components in antiviral and antitumor immunity to OV.
Additionally, NKp46 is the only NCR present on murine NK
cells. As a result, we are limited in our ability to test the
signiﬁcance of NKp44 and NKp30 against OV in vivo.T o
circumvent this problem, it would be possible to evaluate
OV in the context of a humanized mouse model [112]
where NKp46, NKp44, and NKp30 are expressed.
While a variety of cotherapies have been shown co-
operate with viral oncolysis through immune cell suppres-
sion,additionalworkcanbedonetoﬁne-tunethisapproach.
For instance, it is shortsighted to think that antitumor im-
munity has no part in viral oncolysis. Rather, future work
must identify the delicate balance between an initial suppres-
sion of antiviral immunity that facilitates initial rounds of
viral replication and a downstream stimulation of antitumor
immunity against tumor or viral antigens. This could
potentially take the form of targeting NK cell depletion in
a temporal manner whereby NK cells are attenuated initially
after viral infection and then allowed to repopulate the site
of infection a few days after viral inoculation. This later
responsewouldtakeadvantageoftheirantitumorproperties,
macrophage activating properties, and their ability to induce
an antitumor T-cell response.
An additional approach could focus on M1/M2 macro-
phage polarization following OV infection. Clinical reports
have conﬁrmed that tumors, such as glioblastoma, are
typically associated with generalized immunosuppression,
TGF-β production, and an M2 macrophage phenotype
[103]. oHSV inoculation elicits an M1 macrophage response
thatisdetrimentaltoOVeﬃcacy[91].Takentogether,future
studies could attempt to discern whether a temporary main-
tenanceoftheM2phenotypeinitiallyafterinfectionfollowed
by a switch towards an inﬂammatory M1 state is eﬀective
at initially enhancing viral titers while eliciting antitumor
immunity at later timepoints.
The role of NK receptor-ligand interactions deserves
further exploration. Future studies should investigate the
identity of the NK receptor ligands in virally infected cells;
whether the ligands are viral in origin or expressed following
cellularstress;whethertheyareexpressedfollowinginfection
with other oncolytic viral vectors. The identifying of ligands
expressedafterOVinfectionwillbeusefulonmultiplefronts.
First it could potentially be targeted to enhance viral eﬃcacy.
For instance, if NKp30 and NKp46 are key receptors medi-
ating premature viral clearance, suppressing the expression
of these ligands could be particularly advantageous. Targeted
suppressioncouldbeachievedthrougheitherpharmacologic
meansorthroughthecreationofanoveloHSVthatexpresses
a decoy for NKp30/NKp46 or inhibits ligand presentation
on the infected cell surface. Second, while NK killing of
virallyinfectedcellsmaybedeleteriousforviralreplication,it
represents a novel target for mediating antitumor immunity.
As a result, in instances where NK-mediated antitumor
immunityisdeemedbeneﬁcial,suchaslatertimepointsafter
infection once productive viral replication is established,
eliciting NKp30/NKp46-mediated tumor killing could be
pursued as a viable therapeutic option.
With a number of oncolytic viral clinical trials in the
pipeline, it will be critical for investigators to include the
evaluationofNKcellsintheimmunologicalresponsetoviral
administration. Attention should be directed towards NK
cell numbers in the periphery, within the tumor microen-
vironment and their distribution within the virally infected
tumor. Moreover, the activation/developmental stateof these
NK cells should be evaluated. For instance, NK cells should
be tested for CD56 and CD94 expression, whether the
recruited/circulating NK cells are NCRbright or NCRdim,a n d
their functional capacity. By collecting this data from human
samples,wecantestthevalidityofourpreclinicalmodelsand
guide future experimental trials.
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